United Therapeutics (UTHR) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
United Therapeutics (UTHR) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 68.18% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -388.62% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 2,405.06% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | -14.93% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -562.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.68% |
| Dec 31, 2025 | 20.91% |
| Sep 30, 2025 | 9.58% |
| Jun 30, 2025 | 11.29% |
| Mar 31, 2025 | 5.09% |
| Dec 31, 2024 | 38.78% |
| Sep 30, 2024 | 15.51% |
| Jun 30, 2024 | 7.29% |
| Mar 31, 2024 | 27.27% |
| Dec 31, 2023 | 64.35% |
| Sep 30, 2023 | 11.83% |
| Jun 30, 2023 | 123.45% |
| Mar 31, 2023 | 0.42% |
| Dec 31, 2022 | 17.74% |
| Sep 30, 2022 | 47.08% |
| Jun 30, 2022 | -32.79% |
| Mar 31, 2022 | 747.70% |
| Dec 31, 2021 | 13.56% |
| Sep 30, 2021 | -4.96% |
| Jun 30, 2021 | 61.16% |